References in periodicals archive ?
Drugs profiles discussed in this report includes AFM-13, alemtuzumab, alisertib, belinostat, copanlisib, darinaparsin, denileukin diftitox, forodesine hydrochloride, lenalidomide, masitinib, mogamulizumab, pralatrexate, romidepsin, ruxolitinib phosphate, selinexor, SH-7129, TGR-1202.
With $115 million of cash and investments and a projected operating cash burn of approximately $25 million, we believe that we are in an excellent position to advance our core products, belinostat and CR011-vcMMAE, toward registration development during 2008 and to fund operations into 2011," commented Timothy Shannon, MD, President and Chief Executive Officer of CuraGen.
Safety profile suggests belinostat is acceptable for patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL), including difficult-to-treat patients with low platelet counts due to marrow involvement with their disease or poor marrow reserve.
Anders Vadsholt, Topotarget s CEO, also released a statement: The positioning of BioAlliance Pharma, their late stage assets and expertise makes BioAlliance Pharma a perfect fit as a company to merge with, allowing the acceleration of belinostat development in several new orphan oncology indications by leveraging on both team s synergistic expertise.
Belinostat, HDAC inhibitor for the treatment of cancer:
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced surpassing the primary endpoint in the pivotal, registrational Phase 2 BELIEF trial of belinostat, a pan-histone deacetylase (HDAC) inhibitor.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company's strategic focus and the future development and commercialization of CDX-011 or any of our other drug candidates, including rindopepimut (CDX-110), CDX-1135 (formerly TP10), CDX-1401, CDX-1127, CDX-301, Belinostat and any future action we or the FDA (or any other regulator) might take with respect to regulatory approvals.
Singh was the Chief Operating Officer at Spectrum Pharmaceuticals, where he spearheaded numerous strategic and commercial transactions, including the in-licensing of Belinostat.
TopoTarget Successfully Buys Back Full Control of Belinostat, Consolidating the Global Rights for the Product
Three poster presentations for FOLOTYN[R] (pralatrexate injection) and four poster presentations for belinostat, a novel HDAC inhibitor
Shrotriya, MD, Chairman, CEO, and President of Spectrum, said, "Based on the clinical data, belinostat was shown to have an acceptable safety profile and clinical efficacy, with complete responses in heavily pretreated patients.